Johnson & Johnson enters a strategic agreement with Sail Biomedicines, according to reports. Under the terms described by outlets, Johnson & Johnson is scheduled to make total initial payments of $785 million to Sail. The deal also gives Johnson & Johnson an exclusive option to acquire Sail for $2.58 billion. The arrangement positions Johnson & Johnson to evaluate or advance its partnership with Sail before deciding on the potential acquisition. The reported figures indicate a structured commitment: an upfront funding component through initial payments, followed by a separate, larger price if Johnson & Johnson exercises the takeover option. Both the payment amount and the acquisition price are cited as key terms of the agreement. The outlets do not, in the provided excerpts, detail regulatory approvals, timing of the option exercise, or the specific business areas or programs covered by the collaboration. The reporting focuses on the financial structure and the exclusive acquisition option as the central elements of the strategic agreement.